The oral function study of people with HIV/AIDS by HAART

HAART对HIV/AIDS患者口腔功能的研究

• 批准号: 13671997
• 负责人: MATSUMOTO Hiroyuki
• 金额: $ 2.24万
• 依托单位: Tokyo Medical and Dental University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2001
• 资助国家: 日本
• 起止时间: 2001 至 2004
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-13671997/
• 关键词: HAART; AIDS; HIV; dental treatment; CD4; caries; periodontal; 歯周病; CD4陽性リンパ球数; 口腔機能異常; う蝕・歯周炎; 卒後教育; 歯科診療; 口腔疾患; エイズ; 口腔カンジダ; 日和見感染症; 歯科保存学的アプローチ; 唾液; 歯周疾患; 口腔; 口腔カンジタ

We researched the dental treatment status situation about the people with HIV/AIDS (PHA,n=140). There were 8 dental private offices which has treated PHA were agreement with our study.The PHA's age of this research was distributed from 19 to 73 peaked in 30s ages, it was co-related with PHA population, the ratio of male and female was 6:1. Their CD4 level showed 60% of more than 201, which their systematic condition were good level. Although there was no AIDS specified oral disease, the cause by caries, periodontal disease and pulptitis took 85%. There was no significant deference regarding oral disese between non-PHA and PHA. Dental treatment including the operation, which like extraction was parity to non-PHA, too. The ratio of oral dental treatment period was 36% of less than 10 days, 64% was over 11 days.Expecting to increase number and disperse to local area of PHA, this research proposes strongly to introduce dental offices in local area smoothly, to establish cooperation among each medical support and to inform the latest information of oral condition.

我们对艾滋病病毒感染者/艾滋病患者（PHA，n=140）的牙科治疗状况进行了调查。有8家治疗过PHA的私人牙科诊所与我们的研究一致。本次研究的PHA年龄分布在19岁至73岁，高峰在30岁，与PHA人口相关，男女比例为6 ：1。他们的CD4水平显示超过201的60%，他们的系统状况处于良好水平。虽然没有艾滋病特有的口腔疾病，但由龋齿、牙周病和牙髓炎引起的占85%。非 PHA 和 PHA 之间的口腔疾病没有显着差异。包括手术在内的牙科治疗，与拔牙一样，也与非 PHA 相同。口腔牙科治疗时间少于10天的比例为36%，超过11天的比例为64%。本研究强烈建议在当地顺利引入牙科诊所，建立PHA的数量并分散到当地地区。各医疗支持单位之间的配合，通报口腔状况的最新信息。

项目成果

The Joint United Nations Programme on HIV/AIDS 95–95–95 targets: worldwide clinical and cost benefits of generic manufacture

联合国艾滋病毒/艾滋病联合规划署 95–95–95 目标：仿制药生产的全球临床和成本效益

• DOI: 10.1097/qad.0000000000002983
• 发表时间: 2021-06-09
• 期刊: AIDS
• 影响因子: 3.8
• 作者: K. Heath;J. Levi;A. Hill
• 通讯作者: A. Hill